<DOC>
	<DOCNO>NCT02120196</DOCNO>
	<brief_summary>The aim study compare effectiveness rifaximin versus norfloxacin secondary prevention spontaneous bacterial peritonitis patient liver cirrhosis ascites .</brief_summary>
	<brief_title>Comparative Study Rifaximin Versus Norfloxacin Secondary Prophylaxis Spontaneous Bacterial Peritonitis</brief_title>
	<detailed_description>This study carry 100 patient liver cirrhosis ascites enrol Tanta University , Tropical Medicine Department period January 2014 6 month . The selected patient randomly assign receive 400 mg norfloxacin daily 1200 mg rifaximin daily classify two group : Group 1 : 50 patient treated 1200 mg rifaximin daily . Group 2 : 50 patient treat 400 mg norfloxacin daily .</detailed_description>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<mesh_term>Norfloxacin</mesh_term>
	<criteria>Previous episode SBP Total protein ascitic fluid equal 1.5 g/dL Allergy quinolones Antibiotic therapy 2 week precede inclusion Recent ( within previous 2 week ) episode digestive hemorrhage Hepatocellular carcinoma neoplasia able shorten life expectancy Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>